Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Background: 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) is used both recreationally and therapeutically. Little is known about the factors influencing inter- and intra-individual differences in the acute response to MDMA. Effects of other psychoactive substances have been shown to be critically influenced by personality traits and mood state before intake. Methods: We pooled data from 10 randomized, double-blind, placebo-controlled, cross-over studies performed in the same laboratory in 194 healthy subjects receiving doses of 75 or 125mg of MDMA. We investigated the influence of drug dose, body weight, sex, age, drug pre-experience, genetics, personality and mental state before drug intake on the acute physiological and psychological response to MDMA. Results: In univariable analyses, the MDMA plasma concentration was the strongest predictor for most outcome variables. When adjusting for dose per body weight, we found that (a) a higher activity of the enzyme CYP2D6 predicted lower MDMA plasma concentration, (b) a higher score in the personality trait “openness to experience” predicted more perceived “closeness”, a stronger decrease in “general inactivation”, and higher scores in the 5D-ASC (5 Dimensions of Altered States of Consciousness Questionnaire) scales “oceanic boundlessness” and “visionary restructuralization”, and (c) subjects with high “neuroticism” or trait anxiety were more likely to have unpleasant and/or anxious reactions. Conclusions: Although MDMA plasma concentration was the strongest predictor, several personality traits and mood state variables additionally explained variance in the response to MDMA. The results confirm that both pharmacological and non-pharmacological variables influence the response to MDMA. These findings may be relevant for the therapeutic use of MDMA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359 · cited 2×
“3,4-methylenedioxymethamphetamine (MDMA) is known as the recreational drug “ecstasy”, but has recently gained interest as an adjunct in psychotherapy for post-traumatic stress disorder or other anxiety disorders (Danforth et al., 2018; Mithoefer et al., 2010, 2019; Oehen et al., 2013).”
BackgroundRetractedControlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
How Many Imputations are Really Needed? Some Practical Clarifications of Multiple Imputation Theory
Graham, J. W., Olchowski, A. E., & Gilreath, T. D. (2007) · Prevention Science · doi:10.1007/s11121-007-0070-9 · Cited by 2,795 · cited 1×
“We generated 20 imputations of the missing values such that 20 completed datasets were obtained to avoid a potential power falloff from an insufficient number of imputations (Graham et al., 2007).”
MethodMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Psychometric evaluation of the altered states of consciousness rating scale (OAV)
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · cited 2×
“Furthermore, since these three dimensions are heterogenous constructs (Studerus et al., 2010) and since we were most interested in adverse drug reactions, we additionally included the more homogenous “impaired control and cognition” and “anxiety” subscales constructed by Studerus et al.”
BackgroundSelf-citationMithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · cited 2×
“3,4-methylenedioxymethamphetamine (MDMA) is known as the recreational drug “ecstasy”, but has recently gained interest as an adjunct in psychotherapy for post-traumatic stress disorder or other anxiety disorders (Danforth et al., 2018; Mithoefer et al., 2010, 2019; Oehen et al., 2013).”
BackgroundPsychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · cited 3×
“The influence of set and setting has been traditionally studied in the context of psychedelic drugs as responses to these drugs are thought to be particularly dependent on them (Carhart-Harris et al., 2018).”
BackgroundHartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · cited 3×
“However, like any psychoactive drug, the response to MDMA is also influenced by non-pharmacological variables – also often referred to as set and setting (Hartogsohn, 2016; Kirkpatrick and de Wit, 2015).”
BackgroundPredicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Prediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
Self-citation
Cited by
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Sarparast, A., Thomas, K., Malcolm, B., & Stauffer, C. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06083-y · Cited by 88
“Some studies had unique exclusion criteria that may limit the generalizability of outcomes further, such as high levels of neuroticism (Liechti and Vollenweider 2000a, 2000b)— which recently has been shown to predict negative psychological responses to MDMA (Studerus et al. 2021)—or inclusion of only individuals with…”
BackgroundPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“Similarly, high neuroticism has been associated with unpleasant/anxious reactions in 3,4ethylenedioxymethamphetamine (MDMA) therapy (154).”
BackgroundMDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Systematic review of psychometric instruments used in research with psychedelics
de Deus Pontual, A. A., Senhorini, H. G., Corradi-Webster, C. M., Tófoli, L. F., & Daldegan-Bueno, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2079108 · Cited by 36
Okano, L., Jones, G., Deyo, B., Brandenburg, A., & Hale, W. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.965641 · Cited by 24
Metadata
- Authors
- Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-03-30
- Volume
- 35
- Issue
- 5
- Pages
- 556-565
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W3141124634
- Cited by
- 53
- References
- 22
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies. https://app.cochat.ai/papers/10.1177/0269881121998322
- The paper
- Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E. (2021). Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies. Journal of Psychopharmacology. https://doi.org/10.1177/0269881121998322
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.